1spatial Share Discussion Threads

[alwaysbanking] 13/4/2007 11:59

Another tick up due imminently - mounting graphical pressure to move northwards.IMHO

[3frog] 12/4/2007 22:41

geoff


I can't see you needing a change of trousers with spa, theres too much interest in it by other pharmas. Any sudden dips will either by caused by sellers or mm's, both of which are only short term gliches on it's way northwards.

[alwaysbanking] 12/4/2007 21:33

Tricks today by mms, expect same tomorrow, when weak sellers are gone will surpass recent highs 82.5 and beyond.

[alwaysbanking] 12/4/2007 21:28

A considerable amount of skullduggery being used by the mms on this share. Trades on an ADVFN competitor (monieam) are showing a considerable amount of unknown late reported trades on todays schedule some more than 77p upto and including some large buys at 81p. Im not quite sure how the late reported trades are truly representative of todays action but I thought there was only a 24hr delay -if that is the case where are the trades at 81p coming from and what period do they relate to. I'm expecting a 'hike' in the share price tomorrow judging on today. The graphs are solid and imho represent a rise 'big style' tomorrow. The telegraph articles say it all and what would joe public pay for a treatment for cancer or even Aids. I know if it were any member of my family suffering I'd sell everything I owned.
Weekend press will blitz this share and com monday morning expect the recent highs of 82p to be dwarfed. All imho so do you own research but tree shake today got the mms some cheap shares.

[sawbones] 12/4/2007 17:19

bare no, that sb got taken out a long time back if you recall, they closed it against my wishes.

[geoffmanana] 12/4/2007 17:17

Well what a day!
I was out from about mid-day on the boat with the better half on the Norfolk Broads near were we live without a care in the world and have just got back in,so fortunately missed the change of trouser time when the share price dropped to 71p ish.....looked out for you 3frog,but just saw a heron and a couple of marsh harriers.
Feeling very bullish now we seem to have bottomed out....phew!

[digger27] 12/4/2007 14:45

Mike - only a tenth of what I asked for but still rubbing here and on COP.

[mike111d] 12/4/2007 14:35

digger27, as requested, your tick up. Have you been rubbing again - LOL.

[barefoot1] 12/4/2007 14:13

Saw..are yoo in now or just watching?? i know yoo have 1 sb on...anything else??

[sawbones] 12/4/2007 13:47

good posting alwaysbanking- if SPAs delivery method is as good as I hope then this baby will fly to the moon!

[digger27] 12/4/2007 13:24

Could do with a big tick up - at least that becomes visible!! Cant make head or tail of these two charts and then the real time quote shows the bid as being higher than the mid.
Just move it up 20p for gawds sake so I can see it properly...oh the extra money would come in handy too!!!!

[alwaysbanking] 12/4/2007 11:39

A nice tick up expected imminently

[3frog] 12/4/2007 10:57

ooooooooooooooooo nice

[3frog] 12/4/2007 10:54

2 10k's might move us though

[geoffmanana] 12/4/2007 09:38

Yet down we go!
Market forces are in progress?
Big buyer at around 74/75p maybe.

[alwaysbanking] 12/4/2007 09:25

REMEMBER THIS

SR Pharma Granted Core RNAi Patent by the European Patent Office European Patent EP1527176 B1 – Reinforces Company's Leading Position in RNAi Therapeutics London, UK, 3 January 2007 .....

SR Pharma plc (London LSE: SPA), Europe's leading RNAi therapeutics company, today announces that the European Patent Office has granted the Company its core RNAi patent EP1527176 B1. This patent covers its novel, stabilised, small interfering RNA (siRNA) molecules with blunt ends and positional modifications. These proprietary siRNA molecules are referred to as 'AtuRNAi' by SR Pharma. This is the first patent to be granted for this new class of stable siRNA molecules and provides SR Pharma with freedom to operate within the RNAi therapeutics field. The 38 claims in the patent cover AtuRNAi structures that have a well defined positional arrangement of modified nucleotides. These novel siRNA molecules developed by SR Pharma have important advantages over conventional siRNA molecules including increased stability against nuclease degradation and an increased serum half life. These AtuRNAi compounds form the basis of SR Pharma's own therapeutic development pipeline which is focused on cancer indications. The Company's first clinical trials in the cancer field are expected to start in 2007. These molecules also form the basis of the group's licence and collaboration agreement with Quark Biotech Inc. and the recently announced sublicense to Pfizer Inc., whose Phase I clinical trial in Age-related Macular Degeneration using these molecules is expected to start in the near future. Dr Klaus Giese, Chief Scientific Officer of SR Pharma said "This patent is a major step forward for SR Pharma. The broad coverage that we have gained for our novel AtuRNAi molecules reflects our significant understanding of RNAi chemistry. We are confident that we will be able to gain a similar level of patent protection for our AtuRNAi molecules from the US patent office during the course of 2007." Iain Ross, Chairman of SR Pharma, said: "This patent provides us with the freedom to operate within this exciting area of science and validates our unique technology approach. It also puts us in a much stronger position to conclude licensing and corporate development deals which we expect to play a crucial role in our goal to become a global leader in the development of RNAi therapeutics." - Ends - SR Pharma (www.srpharma.com) SR Pharma plc is a European biopharmaceutical company, listed on AIM. The Company has two operating subsidiaries Atugen AG (www.atugen.com) based in Berlin, Germany and Stanford Rook Ltd based in London, UK. SR Pharma is a leader in RNAi therapeutics, which is a Nobel Prize winning technology that "silences" genes linked to the onset of disease. The Company has developed novel, chemically modified proprietary siRNA molecules ("AtuRNAi"), which have a number of advantages over conventional siRNA molecules including enhanced stability against nuclease degradation. In addition, the Company has developed a proprietary delivery system ("AtuPLEX"), which increases bioavailability, circulation times and functional intracellular uptake of siRNA molecules. SR Pharma expects to begin the clinical development of its own AtuRNAi therapeutic molecules for systemic cancer indications in 2007. SR Pharma also has AtuRNAi compounds partnered with Quark Biotech and Pfizer, the lead programme of which is due to commence Phase I trials for Age-related Macular Degeneration in the near future.
In addition, SR Pharma owns a proprietary Mycobacterium vaccae-based technology and related products. Currently the Company is in discussions with third parties regarding the co-development and out-licensing of these products. Forward-Looking Statements This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to SR Pharma and SR Pharma assumes no obligation to update any such forward-looking statements. Enquiries: For further information, please contact the following: SR Pharma plc Citigate Dewe Rogerson [phone] [phone] Iain Ross, Chairman David Dible Melvyn Davies, Finance Director Valerie Auffray Yvonne Alexander Atugen AG [phone] Thomas Christély, Chief Executive Officer Dr. Klaus Giese, Chief Scientific Officer

[alwaysbanking] 12/4/2007 09:19

RNA-i: Discovered in a petunia, found in flies and now causing a medical revolution

Published: 12 April 2007

There is barely an area of biomedical science that has not been touched by the revolutionary technique of RNA-interference (RNA-i), an area of research which won last year's Nobel Prize in medicine because of its importance in modern molecular biology.

RNA-i allows scientists to target a gene with exquisite accuracy by giving them a precise molecular tool for gradually turning down a gene's activity, much like a dimmer switch of an electric light bulb.

RNA-i seems to be one of nature's ways of controlling gene activity and it appears to be ubiquitous among all living cells. Scientists discovered RNA-i in petunia plants in the 1990s, but have since found that it occurs in almost every organism studied, from fungi to fruit flies, from mouse to man.

It is possible that the process of controlling gene activity using RNA-i evolved as a primitive form of defence against the lethal genes of invading viruses, before the evolution of sophisticated immune systems in higher animals.

However, it became apparent that scientists could exploit the phenomenon to target specific genes that they wanted to control. For example, they could use it to shut off the vital genes for an invading virus such as HIV - and there are plans for at least one clinical trial to do just that.

Another idea was to use RNA-i to switch off the genes in a human cell that are essential for the growth of a cancer. If these "oncogenes" are turned off or silenced, the cancer should die. Again, clinical trials are being planned.

A further approach is to turn off the genes that are involved in stimulating the growth of new blood vessels. If this can be done in the eye, for instance, you might have a cure for macular degeneration - when new blood-vessel growth blocks vision in the retina.

One other line of research is to use RNA-i to switch off damaged genes responsible for inherited genetic disorders, such as Huntington's disease. Suddenly it was possible to talk about potential cures for previously untreatable illnesses.

There appears to be no limit to the range of disorders that can be addressed with RNA-i. Now, as the latest study in Nature has shown, the technique may even be used as a method of improving the efficacy and safety of existing - as well as future - anti-cancer drugs.

One of the beauties of the RNA-i approach is that it is relatively easy for scientists to make the necessary drugs. In effect, they are just small strands of the RNA molecule, which can be synthesised automatically by machine. Each strand is about 22 units long - tiny compared with the 3 billion units that make up the entire DNA molecule of the human genome.

Each of these "short-interfering" strands of RNA can be targeted specifically to work against a particular gene, which is one of the reasons why the technique is so attractive. It means there is less chance of cross-reactions or unintended side effects.

However, one of the biggest problems with RNA-i is what is called "delivery" - how do you make sure that the synthetic RNA molecules actually get inside the cells that matter? That is the real problem with using RNA-i on patients. Solve that, and you have a potential treatment for many of the most intractable illnesses known to man.

Two American scientists, Andrew Fire and Craig Mello, won the 2006 Nobel Prize in medicine or physiology for their pioneering research into RNA-i, published in 1998. They worked on nematode worms and, some years later, other scientists found that the phenomenon also occurred in human cells - paving the way for clinical treatments for disorders ranging from heart disease to cancer.

In its citation, the Nobel Assembly said RNA-i promised to be one of the most exciting developments in medical science. "RNA interference is already being widely used in basic science as a method to study the function of genes and it may lead to novel therapies in the future," it said.

[geoffmanana] 12/4/2007 09:15

Thanks rrb.
Shame we are not mentioned by name.

[geoffmanana] 11/4/2007 21:48

Or even a tadpole!

[3frog] 11/4/2007 21:14

tone

will add £20k here too before EGM held on 26th April.(not a big fish but slowly getting there).

[alwaysbanking] 11/4/2007 21:02

Again from my understand (very limited) of the charts the on balance volume is rising significantly into positive territory, imho all bodes well for that tick up to 77 - 78p tomorrow.

[tonester30ccfc] 11/4/2007 17:35

froggie,

biggest holding is MXP. £350k up in 6 weeks. Beats working for a living. SPA next. Sitting on a sizeable core holding. Will be adding

Tone

[3frog] 11/4/2007 17:32

Good PANR day 4 u tone. Hope it gets better with Wilson.

[geoffmanana] 11/4/2007 16:34

Interesting.